A large, consanguineous Saudi family with three members with sialidosis type 1 and five members with infantile central nervous system spongy degeneration of the brain (ICNSSD, or Canavan-Bertrand-van Bogaert disease) is described. The patients with sialidosis had normal aspartoacylase activity, while neuraminidase activity in the patients with ICNSSD was reduced. All patients had normal carboxypeptidase activity in their fibroblasts. In an additional member there was photic-induced epilepsy, but he had normal enzymes. Two of the patients and one normal brother, but not the parents, had pericentric inversion of chromosome 9q. We postulate that an unidentified gene function is responsible for varied expression of these neurodegenerative diseases in this family. (J Child Neurol 1992;7(Suppl):S73-S78.)
Get full access to this article
View all access options for this article.
References
1.
Gascon G., Wallenberg B., Daif AK, Ozand P.: Successful treatment of cherry red spot-myoclonus syndrome with 5-hydroxytryptophan . Ann Neurol1988;24:453-455.
2.
LowdenJA,O'BrienJS: Sialidosis: A review of human neuraminidase deficiency. Am J Hum Genet1979;31:1-18.
3.
Gascon GG, Ozand PT, Mahdi A., et al: Infantile CNS spongy degeneration—14 cases: Clinical update . Neurology1990; 40:1876-1882.
4.
Matalon R., Michals K., Sebesta D., et al: Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet1988;29:463-471.
5.
Ozand PT, Gascon GG, Dhalla M.: Aspartoacylase deficiency and Canavan disease in Saudi Arabia. Am J Med Genet1989;34:266-268.
6.
Subramanyam SB, Tipirneni A., Youssef N., et al: Biochemical heterogeneity of infantile CNS spongy degeneration. J Child Neurol1992 ;7(Suppl):S22-S25.
7.
Ozand PT, Gascon G., Al Aqeel A, et al: Prevalence of different types of lysosomal storage diseases in Saudi Arabia. J Inherited Metab Dis1990 ;13:849-861.
8.
Ozand PT, Gascon GG, Al Aqeel A., et al: Prenatal detection of Canavan disease. Lancet1991;1:735-736.
9.
Ozand PT, Gascon GG: Heterogeneity of carboxypeptidase activity in infantile onset galactosialidosis . J Child Neurol1992;7(Suppl):S31-S40.
10.
Hoogeven AT, Verheijen FW, d'Azzo A, Galjaard H: Genetic heterogeneity in human neuraminidase deficiencyNature1980;285:500-502.
11.
Spranger J., Gehler J., Cantz M.: Mucolipidosis I-A sialidosis. Am J Med Genet1977;1:21-29.
12.
Kelly T., Graetz G.: Isolated neuraminidase deficiency: A distinct lysosomal storage disease . Am J Med Genet1977;1:31-46.
13.
Wolfe LS: Chemical pathology of the sialidoses. Birth Defects1982;18:405-409.
14.
Laver J., Fried K., Beer S., et al: Infantile lethal neuraminidase deficiency (sialidosis). Clin Genet1983;23:97-101.
15.
O'Brien JS: Neuraminidase deficiency in the cherry red spot-myoclonus syndrome. Biochem Biophys Res Commun1977; 79:1136-1141.
16.
Beaudet A., Thomas GH: Disorders of glycoprotein degradation: Mannosidosis, fucosidosis, sialidosis, and aspartylglycosaminuria, in Scriver CR , Beaudet AL, Sly WS, Valle D (eds): The Metabolic Basis of Inherited Disease, 6th ed. New York, McGraw-Hill, 1989, pp 1603-1621.
17.
Verheijen FW , Palmeri S., Hoogeveen AT, Galjaard H.: Human placental neuraminidase—Activation, stabilization and association with beta-galactosidase and its "protective protein." Eur J Biochem1985;149:315-321.
18.
Frisch A., Neufeld EF: A rapid and sensitive assay for neuraminidase: Application to cultured fibroblasts . Anal Biochem1979;95:222-229.
19.
Verheijen FW , Janse HC, van Diggelen OP, et al: Two genetically different Mu-NANA neuraminidases in human leucocytes. Biochem Biophys Res Commun1983;117:470-478.
20.
Ben-Yoseph Y., Momoi T., Hahn LC, Nadler HL: Catalytically defective ganglioside neuraminidase in mucolipidoses IV. Clin Genet1982;21:374-381.
21.
Caimi L., Tettamanti G., Berra B., et al: Mucolipidosis IV, a sialolipidosis due to ganglioside sialidase deficiency. J Inherited Metab Dis1982;5:218-224.
22.
Durand P., Gatti R., Cavalieri S., et al: Sialidosis (mucolipidosis 1). Helv Pediatr Acta1977;32:391-400.
23.
Swallow DM, Hoogeven AT, Verheijen FW, Galjaard H.: Complementation analysis of human sialidase deficiency using natural substrates . Ann Hum Genet1979;45:105-112.
24.
McKusick VA: 25655: Neuraminidase deficiency (sialidoses types 1 and 2), in Mendelian Inheritance in Man, 7th ed. Baltimore, Johns Hopkins University Press, 1986, pp 1158-1161.
Glossl J., Kresse H., Mendla K., et al: Partial deficiency of glycoprotein neuraminidase in some patients with Morquio disease type A. Pediatr Res1984 ;18:302-305.
27.
Baumkotter J., Cantz M.: Decreased ganglioside neuraminidase activity in fibroblasts from mucopolysaccharidosis patients. Inhibition of the activity in vitro by sulfated glycosaminoglycans and other compounds. Biochem Biophys Acta1983; 761:163-170.
28.
Mueller OT, Henry WM, Haley LL, et al: Sialidosis and galactosialidosis: Chromosomal assignment of two genes associated with neuraminidase-deficiency disorders. Proc Natl Acad Sci USA1986;83:1817-1821.
29.
Shimmoto M. , Takano T., Fukuhara Y., et al: Japanese type adult galactosialidosis. A unique and common slice junction mutation causing exon skipping in the protective protein/carboxypeptidase gene. Proc Jpn Acad1990;66(Series B):217-222.
30.
Oohira T., Nagata N., Akaboshi I., et al: The infantile form of sialidosis type II associated with congenital adrenal hyperplasia: Possible linkage between HLA and the neuraminidase gene . Hum Genet1985;70:341-343.
31.
Greenberg DA , Delgado-Escueta AV, Widelitz H., et al: Juvenile myoclonic epilepsy may be linked to the BF and HLA loci on human chromosome 6. Am J Med Genet1988;31:185-192.
